Prima BioMed (NASDAQ:IMMP) Shares Cross Below Fifty Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP)’s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.39 and traded as low as $0.3550. Prima BioMed shares last traded at $0.3551, with a volume of 107,492 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Maxim Group raised Prima BioMed from a “hold” rating to a “buy” rating in a report on Wednesday, June 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Prima BioMed in a report on Friday, July 10th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $5.50.

Prima BioMed Price Performance

The company has a fifty day moving average price of $0.39 and a two-hundred day moving average price of $0.66.

Prima BioMed (NASDAQ:IMMP) last issued its quarterly earnings results on Thursday, July 30th. The biotechnology company reported ($0.09) earnings per share for the quarter. The company had revenue of $3.68 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Prima BioMed stock. Jane Street Group LLC raised its holdings in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the quarter. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 as of its most recent filing with the SEC. 2.32% of the stock is owned by institutional investors and hedge funds.

Prima BioMed Company Profile

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.